Antisense-mediated exon skipping for duchenne muscular dystrophy

1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Duchenne muscular dystrophy (DMD) is a severe, progressive neuromuscular disease for which there is currently no cure available. The disease is caused by mutations in the dystrophin-encoding DMD gene that disrupt the open reading frame and completely abolish dystrophin function. Antisense-mediated exon skipping is a promising approach that is close to clinical application. It aims to modulate pre-mRNA splicing such that the reading frame is restored, allowing for the generation of partly functional dystrophin proteins, as found in less severe Becker muscular dystrophy. Proof-of-principle for this approach has been obtained in patient-derived cell cultures and animal models carrying different types of mutations (deletions, duplications, small mutations and splicing mutations). In theory this approach should be applicable to almost 80% of all patients, but as different exons need to be skipped to restore various mutations, skipping a single exon is beneficial to a subset of patients. All DMD exons can currently be skipped and antisense oligonucleotides to induce exon 51 skipping (applicable to the largest group (13%) of patients) are in the early phase of clinical trials.

Cite

CITATION STYLE

APA

Aartsma-Rus, A., & Van Ommen, G. J. B. (2010). Antisense-mediated exon skipping for duchenne muscular dystrophy. In Muscle Gene Therapy (pp. 69–84). Springer New York. https://doi.org/10.1007/978-1-4419-1207-7_5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free